MIRM Mirum Pharmaceuticals Inc

$MIRM yes yes they all want to come back now. Look at that confidence mgt showed in volixi NDA! 🤩 and growth 10-15 MUSD/q

$MIRM Beats consensus sales by 4%, raises 2026 sales guidance to 3% (midpoint) above consensus.

$MIRM looks like phase 3 news is coming out here tomorrow morning. Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases "today announced that it will host an investor call on Monday, October 12, 2026 at 8:30 a.m. ET/5:30 a.m. PT to share topline results from the Phase 3 EXPAND study evaluating LIVMARLI® (maralixibat) for the treatment of cholestatic pruritus in patients aged 6 months or older with ultra-rare cholestatic liver diseases, including biliary atresia."

$MIRM Consensus sales are nearly flat vs Q2, and Mirum has never been flat. Progress on volixibat with the FDA is going to be closely watched.

$MIRM makes me feel better that an insider bought. I know it was a stock option, but the price he paid was $86. Must feel good about something to go through with buying it.

$MIRM this is manipulation in a stock with low volume with institutional owners. It happens all the time. We can be sure there is already a bid in the background (they are possibly using the volixibat temporary weakness after initial FDA discussions) We should NOT take a bid around 130.

$MIRM wow some crazy manipulation is going on here. An FDA approval and 2 positive phase 3 read outs and we are still down 10-30%..

$MIRM - convincing phase 3 win in biliary atresia, highly competent mgmt team continues to execute

$MIRM on the R&D: "[expenses] have been around 50% of revenue. We think that is going to continue at about that pace for two more quarters, and then subsequently decrease quite rapidly, I think, to 10% of revenue. That should be true long term as well". This means Mirum is going to be profitable next year.

$MIRM 🏥 Mirum Pharmaceuticals announced positive results from Cohort 2 of the pivotal PROGRESS study of ATEBRIOZ (zilurgisertib) in pediatric patients aged 6 to <12 years with fibrodysplasia ossificans progressiva, showing reduced total heterotopic ossification lesion volume and improved clinician-assessed joint mobility at Week 24, with no treated patients developing new lesions. Curated for market relevance

$MIRM gives a solid entry point if this keeps selling off. IMO take over target . Very derisked .

Raymond James⬆️ $MIRM's PT to $189 from $183 and reiterated Strong Buy after 3Q26 earnings. [INCY IPSEY REGN] Raymond James said in its note: Mirum reported another beat-and-raise quarter driven by growth in adult PFIC patients treated with Livmarli. We think Mirum's commercial momentum will continue into 2027, with the newest launch in the portfolio (Atebrioz) now underway, which will be further complemented by three major readouts (AZURE-4 in 4Q26, PBC in 1Q27, and FXS in 2027) as well as four regulatory submissions before year-end 2027. We are making several changes to our model, including the addition of independent market models for biliary atresia (BA) and fibrodysplasia ossificans progressiva (FOP).

$MIRM sales pretty flat. Volixi must be resolved with FDA. I see it as likely they await vantage data to increase at least safety knowledge before moving on with an NDA.

$MIRM only getting stronger yet share price is dropping dont get fooled know what you own and keep adding on dips the share price belongs in the $175+ the science has not changed!

$MIRM, a rare-disease drugmaker, said LIVMARLI met its primary itch endpoint (p=0.0004) in the 52-patient Phase 3 EXPAND trial in ultra-rare liver diseases including biliary atresia. Diarrhea, already a labeled side effect, hit 64% on drug vs 11.1% on placebo; Grade 3+ adverse events were 24.0% vs 22.2%. All 5 secondary endpoints were also met. LIVMARLI is its top seller: $128.7M of $176.2M Q2 2026 sales; 2026 sales guidance is $680M-$700M. Next: a US sNDA in the first half of 2027. Shares closed $85.96 on Oct 9, 2026.

$MIRM Follow-up: ATEBRIOZ shrank HO lesion volume 8.09 cm³ in kids 6 to <12 while placebo grew 9.14 cm³, in a 25-child trial with only a nominal p=0.003. 🏢 Mirum Pharmaceuticals is a rare-disease drugmaker whose ATEBRIOZ won FDA approval on September 25, 2026 for FOP, a disease that grows bone in soft tissue, in patients 12 and older, and its September 28, 2026 8-K said only that the Cohort 2 enrollment of children 6 to <12 was complete ⚠️ The other side is that only 12 children got the drug in the 24-week placebo-controlled period, the p-value is nominal, and the trial measured total HO lesion volume rather than the total new HO volume the drug was approved on, so the FDA review is not a formality 📅 Next: Mirum plans an sNDA in H1 2027 to add ages 6 to <12, with full Cohort 2 data at an upcoming medical meeting Source: Business Wire release, Oct 26 + SEC 8-K, Sep 28

$MIRM MIRM hit endpoints Mirum Says Phase 3 EXPAND Met Primary Endpoint For LIVMARLI In Ultra-Rare Cholestatic Liver Diseases

$MIRM reported earnings after the close yesterday. GAAP EPS missed estimates: -$0.87 vs. -$0.49 expected, according to Stock Meadow.

$MIRM Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.87 down -1840.00% YoY • Reported revenue of $185.72M up 39.63% YoY • Mirum expects total product sales of approved medicines to continue to increase on an annual basis and anticipates net losses for the foreseeable future; no quantified financial range was provided.